ROSIGLITAZONE TREATMENT IN PATIENTS WITH CUSHINGS DISEASEROSIGLITAZONE TREAT

库欣病患者的罗格列酮治疗 罗格列酮治疗

• 批准号: 7718035
• 负责人: ANTHONY P HEANEY
• 金额: $ 0.32万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718035
• 关键词: Adrenal Gland Hyperfunction; Adrenal hormone preparation; Amyloid; Blood Vessels; C-reactive protein; Cell Adhesion Molecules; Computer Retrieval of Information on Scientific Projects Database; Cushing Syndrome; Exhibits; Funding; Grant; Growth; Hormonal; Hormones; In Vitro; Inflammatory; Institution; Interleukin-6; Ligands; Medical; Modeling; Newly Diagnosed; PPAR gamma; Patients; Peroxisome Proliferator-Activated Receptors; Phase II Clinical Trials; Pituitary Gland; Pituitary Neoplasms; Pituitary-dependent Cushing' s disease; Plasma; Research; Research Personnel; Resources; Role; Serum; Sialic Acids; Source; Testing; United States National Institutes of Health; in vivo; rosiglitazone; steroid hormone; tumor; tumor growth

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Specific Aim: PPAR-? ligands are a useful and safe medical therapy for Adrenocorticotrophic Hormone (ACTH)-secreting pituitary tumors (Cushing s disease). As ACTH-secreting pituitary tumors exhibit abundant peroxisome proliferator activated receptor-gamma (PPAR-?) expression and the PPAR-? ligand rosiglitazone exerts potent anti-hormonal and anti-proliferative effects in in vitro and in vivo corticotroph tumor models, the effects of rosiglitazone on pituitary tumor growth, and pituitary tumor ACTH and adrenal steroid hormone secretion will be tested. The potential role of the PPAR-? ligand rosiglitazone in treating Cushing s disease will be examined in a Phase II clinical trial involving 15 patients with ACTH-secreting pituitary tumors (Cushing s Disease), who are newly diagnosed. The study will examine: (1) effects of rosiglitazone treatment on abrogating hypercortisolism, and (2) effects of rosiglitazone treatment on abrogating pituitary corticotroph growth. Additionally the effects, if any, of rosiglitazone treatment on abrogating plasma ACTH levels and inflammatory markers (C-reactive protein, IL-6, serum sialic acid, soluble intracellular and vascular adhesion molecules (sICAM-1, and sVCAM-1), and amyloid A) will be examined.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标 具体目标：PPAR-？配体是用于促肾上腺皮质激素（ACTH）分泌型垂体瘤（库欣病）的有用且安全的药物疗法。 由于分泌ACTH的垂体瘤表现出丰富的过氧化物酶体增殖物激活受体-γ（PPAR-？）表达和过氧化物酶体增殖物激活受体-？配体罗格列酮在体外和体内促肾上腺皮质激素细胞肿瘤模型中发挥有效的抗激素和抗增殖作用，将测试罗格列酮对垂体肿瘤生长以及垂体肿瘤ACTH和肾上腺类固醇激素分泌的作用。 PPAR的潜在作用-？将在II期临床试验中检查配体罗格列酮治疗库欣氏病的作用，该试验包括15名新诊断的ACTH分泌型垂体瘤（库欣氏病）患者。这项研究将审查：（1）罗格列酮治疗对消除皮质醇增多症的作用，和（2）罗格列酮治疗对消除垂体促肾上腺皮质激素生长的作用。此外，将检查罗格列酮治疗对消除血浆ACTH水平和炎症标志物（C-反应蛋白、IL-6、血清唾液酸、可溶性细胞内和血管粘附分子（sICAM-1和sVCAM-1）和淀粉样蛋白A）的影响（如果有）。